Three commonly prescribed statins are best placed to lower all the ‘bad’ types of cholesterol and prevent cardiovascular disease in people with diabetes, according to a new meta-analysis
Two leading Manchester University NHS Foundation Trust (MFT) researchers have been appointed Senior Investigators by the National Institute for Health Research (NIHR).
The results of the world’s first Phase 3 trials, of a new drug Gefapixant, show that it can ease the often distressing symptoms of chronic cough, with minimal side effects.
The MFT-hosted NIHR Manchester Clinical Research Facility (MCRF) has received a £15.5 million award, widening opportunities for people across Greater Manchester to participate in research.